The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $1.70

Today's change-0.11 -6.08%
Updated June 27 4:00 PM EDT. Delayed by at least 15 minutes.
 

Infinity Pharmaceuticals Inc

Nasdaq: INFI
Last

(U.S.) $1.70

Today's change-0.11 -6.08%
Updated June 27 4:00 PM EDT. Delayed by at least 15 minutes.

Infinity Pharmaceuticals Inc crosses below 20-day moving average

Infinity Pharmaceuticals Inc closed sharply lower Tuesday, dropping (U.S.)$0.11 or 6.08% to (U.S.)$1.70 and crossing below its 20-day moving average. Shares have lost 11.46% over the last five days, but have gained 25.93% over the last year to date. This security has outperformed the S&P 500 by 9.83% during the last year.

Key company metrics

  • Open(U.S.) $1.80
  • Previous close(U.S.) $1.81
  • High(U.S.) $1.83
  • Low(U.S.) $1.70
  • Bid / Ask(U.S.) $1.66 / (U.S.) $2.24
  • YTD % change+25.93%
  • Volume538,463
  • Average volume (10-day)929,496
  • Average volume (1-month)503,814
  • Average volume (3-month)835,835
  • 52-week range(U.S.) $0.84 to (U.S.) $3.84
  • Beta2.63
  • Trailing P/E130.27×
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.01
Updated June 27 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.23%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue0009
Total other revenue--------
Total revenue0009
Gross profit--------
Total cost of revenue--------
Total operating expense102320-44
Selling / general / administrative69716
Research & development4151353
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-10-23-2053
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax-10-23-1953
Income after tax-10-23-1953
Income tax, total--00--
Net income-10-23-1953
Total adjustments to net income--------
Net income before extra. items-10-23-1953
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-10-23-1953
Inc. avail. to common incl. extra. items-10-23-1953
Diluted net income-10-23-1953
Dilution adjustment------0
Diluted weighted average shares50505049
Diluted EPS excluding extraordinary itemsvalue per share-0.21-0.46-0.391.07
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.21-0.46-0.391.07